View the latest news and SEC filings
Scroll to
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
May 3, 2017 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
May 1, 2017 |
CT ORDER |
CT ORDER |
Other |
|
|
April 28, 2017 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
April 28, 2017 |
Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 |
424B4 |
Registration Statements |
|
|
April 26, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 26, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
Registration of up to an additional 20% of securities for an offering filed on an F-1 |
F-1MEF |
Registration Statements |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
